Isolation of Human Eosinophil Phospholipase D

LAURENCE A. KATER,† EDWARD J. GOETZL, and K. FRANK AUSTEN

From the Departments of Medicine, Harvard Medical School and Robert B. Brigham Hospital, Boston, Massachusetts 02120

ABSTRACT Phospholipase D preferentially contained in human eosinophil polymorphonuclear leukocytes as compared to other leukocytes was isolated by sequential anion and cation exchange chromatography and gel filtration. The purified eosinophil enzyme specifically liberated choline from l-α-phosphatidyl choline with a pH optimum of 4.5–6.0 and exhibited a pI of 5.8–6.2 on polyacrylamide-gel isoelectric focusing, which are properties shared by phospholipase D from plant sources; however, its apparent mol wt of 60,000 is approximately one-half that of the plant enzymes. Eosinophil and cabbage phospholipase D inactivated a partially purified rat platelet-activating factor (PAF) in a time- and dose-dependent reaction. The cleavage of this PAF activity was attributed to the inherent phospholipase D activity of the eosinophil enzyme since the two activities chromatographed together at each purification step, and there was apparent reciprocal inhibition of choline-generating activity by PAF and of PAF-inactivating activity by phosphatidyl choline. Thus, possible regulatory functions of the eosinophil in immediate hypersensitivity reactions include inactivation of a PAF by phospholipase D as well as degradation of slow-reacting substance of anaphylaxis by arylsulfatase B.

INTRODUCTION

Mixed leukocytes from actively sensitized rabbits interact with specific antigen to release a soluble factor, platelet-activating factor (PAF),† which causes the secretion of amines from normal rabbit platelets (1–4). The basophil polymorphonuclear leukocyte sensitized with IgE is the source of PAF (4, 5). PAF activities were also derived by prolonged incubation of rabbit or human mixed peripheral leukocytes in alkaline buffer (6), by addition of the calcium ionophore A23187 to human leukemic basophils (7), and by IgE-dependent reactions in human leukocyte suspensions (6) and lung tissue fragments (8). PAF obtained from rabbit or mixed human leukocytes incubated in alkaline buffer exhibited cationic characteristics on ion-exchange chromatography, filtered with an apparent mol wt of 1,100 on Sephadex LH-20, and chromatographed on silica thin-layer plates in a region staining for phospholipid (9).

To obtain quantities of a PAF activity sufficient for purification and characterization of its enzymatic susceptibility, the activity was generated in the peritoneal cavity of rats prepared with hyperimmune rat antisera and challenged with specific antigen (10). The PAF activity generated exhibited an apparent mol wt of 300–500, and was susceptible to inactivation by cabbage phospholipase D, but not by phospholipases A and B or mild base hydrolysis (11). Since the eosinophil polymorphonuclear leukocyte has the capacity to inactivate other mediators of immediate-type hypersensitivity reactions (12), eosinophils were examined as a source of phospholipase D capable of destroying this PAF activity.

METHODS

Phospholipases A and B, pronase, and subtilisin (Calbiochem, Los Angeles, Calif.), phospholipases C (Clostridium welchii) and D (cabbage), l-α-phosphatidyl choline, limpet arylsulfatase, and choline iodide (Sigma Chemical Co., St. Louis, Mo.), human serum albumin and ovalbumin (Miles Laboratories, Inc., Elkhart, Ind.), heparin (sodium heparin injection, USP, Upjohn Co., Kalamazoo, Mich.), Sephadex, Blue dextran, and Ficoll (Pharmacia Fine Chemicals, Piscataway, N. J.), dihexanoyl l-α-lecithin (Supelco, Inc., Bellefonte, Pa.), silica gel G thin-layer plates (Brinkmann Instruments, Inc., Westbury, N. Y.), 2,7'-dichlorofluorescein spray (EM Laboratories, Inc., Elmsford, N. Y.), phosphatidic acid (Grand Island Biological Co., Grand Island, N. Y.) [2-3H(N)]5-hydroxytryptamine bisoxalate (10°C)-serotonin and Aquasil Universal LSC Cocktail (New

†This study represents in part the investigations into the cellular regulation of the inflammatory response by Dr. Laurence A. Kater, whose untimely death occurred during a fellowship supported by the National Institutes of Health (AM-05076), in the Departments of Medicine, Harvard Medical School and Robert B. Brigham Hospital, Boston, Mass.

Dr. Goetzl is an investigator of the Howard Hughes Medical Institute.

Received for publication 6 October 1975 and in revised form 20 December 1975.

†Abbreviations used in this paper: PAF, platelet-activating factor; SPB, standard platelet buffer; SRS-A, slow reacting substance of anaphylaxis.

The Journal of Clinical Investigation Volume 57 May 1976-1173-1180 1173
the animals were sacrificed, the peritoneal fluids were harvested and pooled, and 50-ml portions were centrifuged at 100 g for 15 min at 4°C. The supernate was deproteinized by the addition of 4 vol of absolute ethanol and centrifuged at 10,000 g for 15 min at 4°C, evaporated to dryness in a vacuum desiccator (Buchler Instruments, Fort Lee, N. J.), and resuspended in 1.8 ml distilled water. The suspension was incubated with 0.2 ml 1 N NaOH at 37°C for 30 min and 1.8 ml applied to a 0.9 × 30-cm column of Amberlite XAD-2. The column was eluted with 30 ml of distilled water, and then with 30 ml of 80% ethanol in water. The 80% ethanol eluate, containing the bulk of PAF activity, was evaporated to dryness, resuspended in 2.0 ml of 100% ethanol, and applied to a 0.9 × 30-cm column of siliconic acid. The column was sequentially eluted with 30-ml portions of hexane, methylene chloride, acetone, n-propanol, and ethanol: ammonium hydroxide: water (6:3:1 vol/vol) (14). The fractions were evaporated to dryness and re-suspended in 2.0 ml of SPB++ (13) for assay of their platelet-activating activity. The PAF activity was present only in the ethanol: ammonia: water eluate.

In a comparable isolation procedure the ethanol: ammonia: water fraction from the siliconic acid step was lyophilized and resuspended in 2 ml of 80% ethanol and applied to a 1.5 × 70-cm column of Sephadex LH-20. The column was equilibrated and developed with 80% ethanol in water. 100-μl portions of each 2.2 ml fraction were assayed for PAF activity and for slow reacting substance of anaphylaxis (SRS-A) by diluting the portions in the appropriate buffer for each assay (Fig. 1). PAF activity filtered as a single peak with an apparent mol wt of 300–500, presenting within a region which also contained SRS-A. The capacity of the rat PAF activity purified through siliconic acid to release radiolabeled serotonin from human platelets exhibited a steep dose-response in the range of 0–40% net release with PAF at dilutions of 1:1,000 to 1:100 and all assays of PAF activity utilized dilutions in this range (Fig. 2).

Preparation of cell extracts as a source of phospholipase D. Blood from normal subjects and patients with peripheral blood hypereosinophilia was drawn into citrate anticoagulant with or without 1 g/100 ml of dextran (13). The tubes with dextran were incubated for 45 min at 37°C to allow eosinocyte sedimentation; the contaminant leukocyte-rich plasma was aspirated and centrifuged at 100 g for 15 min at room temperature to yield a pellet of mixed leukocytes. This preparation obtained from eosinophil-rich donors was the source of eosinophils and that obtained from normal donors served as a source of polymorphonuclear and mononuclear leukocytes for fractionation on cushions of Hypaque-Ficoll (16). Blood harvested without dextran was spun at 100 g for 15 min at room temperature; the supernate was aspirated as a source of platelets and the lower layer of the cone of packed cells was utilized as a source of eosinocytes. The platelets were then sedimented at 800 g for 15 min at room temperature. Each cell preparation was washed twice and suspended in SPB+. A sample was taken to determine total cell count and differential, and the remaining cells were frozen and thawed three times and sonicated on ice (Ultrasonic Instruments, Inc., Farmingdale, N. Y.) in 30-s bursts for a total of 5 min.

Phospholipase D assay. Phospholipase D of cabbage origin or present in eosinophil extracts and their chromatographic fractions was assayed by its ability to cleave choline from L-α-phosphatidyl choline; choline was quantitated by formation and colorimetric detection of choline enneaideiod (15). γH ml of enzyme source was mixed with 0.1 ml of 0.1 M acetate buffer, pH 5.5 containing 1 mM CaCl₂; and
FIGURE 1 Sephadex LH-20 chromatography of PAF. The pooled and concentrated ethanol:ammonia:water fraction from the silicic acid step was applied to a column of bed volume 124 ml which was run at a flow rate of 6 ml/h. Fractions of 2.2 ml were collected and 100-μl portions of each fraction were assayed in duplicate for each mediator. PEG, polyethylene glycol.

0.1 ml of 4 mM L-α-phosphatidyl choline in 100% ethanol was then added. The mixture was incubated at 37°C for 1 h. The reaction was stopped by the addition of 1 ml CHCl₃-methanol (2:1, vol/vol), and the chloroform-rich lower phase containing unreacted substrate was aspirated and discarded. The upper phase was extracted twice with 1 ml CHCl₃-methanol (17:3, vol/vol) and the lower phase discarded each time. The upper phase was heated at 70°C for 30 min to evaporate organic solvents, cooled to room temperature, and developed with 0.1 ml of 25% (wt/vol) trichloroacetic acid containing 0.025 μmol of choline iodide and 0.2 ml of iodine reagent (15.6 g of I₂ and 20 g of KI/100 ml water). The reaction mixtures were placed at 4°C for 30 min for formation of the choline enneaiodide precipitate. After centrifugation at 1,000 g for 15 min at 4°C the supernate was aspirated and discarded. The precipitate was washed with cold distilled water, dissolved in 1 ml of CHCl₃ with mechanical agitation, and further diluted with 4 ml CHCl₃. Mixtures for a standard curve were prepared by addition of the developing reagents and CHCl₃ to tubes containing 0.05, 0.1, and 0.2 μmol of choline iodide. The optical density of the standard curve and of the experimental mixtures was determined at 365 nm by setting the reagent blank at zero. The reagent blank was prepared and processed as for the experimental samples with additional buffer replacing the enzyme. 1 U of phospholipase D activity was defined as the amount that generated 1 μmol of choline in 1 h at 37°C.

RESULTS

Partial purification of human eosinophil phospholipase D. Cell preparations enriched for a particular cell type were extracted to determine whether any of the peripheral blood cells contained phospholipase D. The sonicates containing the equivalent of 5 × 10⁶/ml for eosinophils, 5 × 10⁷/ml for neutrophils and mononuclear cells, 5 × 10⁶ for platelets, and 5 × 10⁷ for erythrocytes were centrifuged at 800 g for 15 min at room temperature; the supernates were decanted, and 0.1-ml portions were assayed directly and after further dilution for phospholipase D activity. The undiluted eosinophil extract generated 4.8 μmol of choline/h, 1.5 when diluted so as to be equivalent to 5 × 10⁶ cells/ml, and 0.2 when further 10-fold diluted. None of the undiluted extracts from the other cell types demonstrated choline generation; inactivation of PAF was less than 5% of that achieved with extracts of a comparable number of eosinophils. That the eosinophil is a principal source of phospholipase D in peripheral leukocytes was further documented by determining the relationship in 26 hyper eosinophilic subjects between the number of peripheral eosinophils and the capacity of extracts of mixed leukocytes to hydrolyze L-α-phosphatidyl choline (Fig. 3). There was a correla-

Figure 2 Dose-response relationship of silicic acid-purified PAF activity.

Figure 3 Relationship between phospholipase D activity and the number of eosinophils in 1 ml of suspensions of mixed human leukocytes. ○ denotes the patient from whom the enzyme was purified.

Isolation of Human Eosinophil Phospholipase D 1175
tion coefficient of 0.65 for the quantity of phospholipase D and the number of eosinophils per milliliter of mixed leukocytes. The mean phospholipase D content per 10⁶ eosinophils for these patients was 0.25 U (range 0.024 - 0.562 U).

A single subject (denoted by the open circle on Fig. 3) with a peripheral leucocyte count ranging from 18,000 to 33,000/mm³ with 80-93% eosinophilia was utilized as a source of eosinophil phospholipase D for purification. 3 X 10⁶ mixed leukocytes containing 88% eosinophils were suspended in 3.0 ml Hanks’ balanced salt solution, frozen, and thawed three times and sonicated as above. The material was centrifuged at 800 g for 15 min at room temperature, and the supernate was dialyzed against two changes of 1,000 ml each 0.1 M Tris-HCl buffer, pH 8.1, at 4°C overnight and applied to a 1.5 X 25-cm column of DE-52 equilibrated with the same buffer. The column was eluted with two bed volumes of the equilibrating buffer, followed by a linear salt gradient to 0.2 M NaCl in starting buffer. 100-μl portions of each fraction were analyzed for choline-generating and PAF-inactivating activity. The choline-generating and PAF-inactivating activities eluted together at approximately 6-8 mS (Fig. 4). Fractions 113-120 containing both activities were pooled, concentrated to 2 ml, and filtered on a 1.5 X 70-cm Sephadex G-100 column in 0.1 M acetate buffer, pH 5.5. 100-μl portions of each fraction were assayed for choline-generating and PAF-inactivating activities (Fig. 5). Both activities filtered in a single peak at an approximate mol wt of 60,000. Fractions 40-48 were concentrated to 2 ml and applied to a 1.5 X 25-cm column of CM-52 in 0.1 M acetate buffer, pH 5.5. The column was eluted with two bed volumes of equilibrating buffer followed by a linear salt gradient to 0.3 M NaCl at a rate of 20 ml/h. 100-μl portions of each 4 ml fraction were assayed as above. Both activities appeared only in the effluent, which upon concentration to 2 ml contained 40% of starting extract activity in a 162-fold purification based upon total protein assessed by a modification of the Folin method (17). The sp act was 156 U/mg, and a comparable sp act of 194 U/mg was achieved when the isolation procedure was repeated on the cells of the same donor obtained on another occasion. Isoelectric focusing of 10 U of purified phospholipase D with ampholytes in the range of 3-10 revealed concurrent peaks of choline-generating and PAF-inactivating activities which were isoelectric at a pH of 5.8-6.2 (Fig. 6). Parallel gels stained for protein showed a band corresponding to the enzyme activity, and four contaminating bands, the closest being at a pI of 5.1.

The specificity of the phospholipase D and the evidence that a single activity was responsible for the cleavage of phosphatidyl choline was corroborated by thin-layer chromatographic analysis of digestion mixtures. 1 U of phospholipase D was incubated with 100 μl of 4 mM synthetic dihexanoyl-L-a-lecithin at 25°C for 6 or 18 h. Each replicate was extracted with 1 ml of chloroform, methanol (2:1, vol/vol) in two portions, and the organic phase desiccated to 100 μl and spotted on silica gel plates. The plates were developed with chloroform:methanol:water (80:35:5, vol/vol).

![Figure 4 DE-52 chromatography of eosinophil extract. Column bed volume was 44 ml, flow rate was 18 ml/h, and fraction volume was 4 ml. Choline generation was not plotted for the regions of the chromatogram in which it was not detected.](image-url)
The only product detected after spraying with 2',7'-dichlorofluorescein was phosphatidic acid identified by co-chromatography of a purified standard.

The pH optimum of eosinophil phospholipase D was defined by interacting 2 U with the standard lecithin substrate concentration in 0.1 M acetate buffer ranging in pH from 3.5 to 6.0, and in 0.1 M Tris-HCl buffer ranging in pH from 6.5 to 9.5, at 37°C for 1 h. The pH optimum was 4.5-6.0, compatible with that reported for phospholipase D of cabbage and peanuts (18-20).

100 μl of rat PAF activity purified through silicic acid was incubated with 0.1 ml of 1 mg/ml pronase, subtilisin, and phospholipases A and B, in a final volume of 200 μl of SPB++, pH 7.2 at 37°C for 2 h. Identical portions of PAF were incubated with limpet arylsulfatase, 10 mg/ml, and cabbage phospholipase D, 1 mg/ml, in 0.1 M acetate buffer pH 5.5 for 2 h at 37°C. Phospholipase D treatment decreased PAF activity by 40% whereas the other enzymes failed to diminish its capacity to release [14C]serotonin from platelets.

Inactivation of a PAF activity by eosinophil and cabbage phospholipase D. Phospholipase D from cabbage source, 250 U in 2.0 ml 0.1 M acetate, pH 5.5 was filtered on a 1.5 × 70-cm Sephadex G-100 column equilibrated with the same buffer, and the peak activity was pooled and concentrated to 2.0 ml, 85 U/ml. Cabbage phospholipase D filtered just after the front compatible with the published approximate mol wt of 100,000 (18, 20) and concentrations of the active fractions revealed 60% recovery with a sp act of 6.5 U/mg. This preparation was compared with the purified eosinophil phospholipase D, 156 U/mg, in terms of the dose-responses for choline generation using the standard substrate concentration, and destruction of PAF employing a 1:20 dilution of the usual silic acid-purified material. The reaction was carried out in 0.1 M acetate buffer, pH 5.5 at 37°C for 1 h in the case of choline generation and 2 h for PAF inactivation. Choline generation was directly assayed, while the pH of the reaction mixture containing PAF was adjusted to 7.2 with 1 M sodium acetate and

**Figure 5** G-100 chromatography of eosinophil phospholipase D. Column bed volume was 124 ml, flow rate was 10 ml/h, and fraction volume was 2 ml.

**Figure 6** Isoelectric focusing of eosinophil phospholipase D.
diluted to 1:200 before assay of residual PAF. As shown in Fig. 7, partially purified cabbage phospholipase D and crude and purified eosinophil phospholipase D yielded a dose-related liberation of choline and inactivation of PAF. At high enzyme concentrations choline-generating activity fell below the unit activity values obtained by analysis of diluted samples. The comparable activity of the crude and purified eosinophil phospholipase D would suggest that the increase in specific activity during purification was not due principally to removal of an inhibitor.

The time-course of PAF inactivation by purified eosinophil phospholipase D at a dose of 5 U was examined at 37°C as described for the dose-response analysis. PAF inactivation was apparent after 10 min and complete by 90 min (Fig. 8). PAF incubated in buffer alone lost no activity during the 2 h of observation, and 5 U of enzyme incubated in buffer for the same time period had no effect on the platelets.

The effect of varying concentrations of silicic acid-purified PAF on the choline-generating activity of 0.6 U of eosinophil phospholipase D was determined under the standard reaction conditions of 1 h at 37°C. The suppression of choline generation was 32, 59, and 68% with the respective presence of 1:800, 1:400, and 1:200 dilutions of PAF. In an additional experiment, 0.5 U of purified eosinophil phospholipase D was incubated with a 1:200 dilution of PAF alone and in the presence of increasing amounts of lecithin for 2 h at 37°C. PAF alone yielded 37% net release of [14C]-serotonin. The PAF incubated with enzyme in the absence of lecithin was 85% inactivated, while 0.1, 1, and 5 μmol of lecithin achieved an incremental protection...
such that the residual PAF activity was 12, 38, and 80% of that incubated in buffer alone.

**DISCUSSION**

The unique association of phospholipase D with human polymorphonuclear leukocytes of the eosinophil class is appreciated by the relationship of total extractable phospholipase D in a mixed cell pool of human leukocytes to its content of eosinophils (Fig. 3). The allocation of phospholipase D to the eosinophil is corroborated by the extraction of this activity from populations of human leukocytes containing more than 88% eosinophils, from a single donor on two occasions, and by the absence of such activity from preparations of polymorphonuclear leukocytes, mononuclear leukocytes, platelets, and erythrocytes at comparable cell concentrations. The eosinophil content of phospholipase D in the donor from whose cells the enzyme was purified was 0.066 U/10^6 eosinophils which fell in the midregion of the range for levels of 25 other donors of 0.024-0.562 U/10^6 eosinophils (Fig. 3). The eosinophil phospholipase D chromatographed as a single peak on DE-52 (Fig. 4), Sephadex G-100 (Fig. 5), and CM-52, with an overall recovery of approximately 40%. Isoelectric focusing of the purified enzyme also revealed a single peak of activity, as well as the presence of at least four contaminating proteins without this activity (Fig. 6). Thin-layer chromatographic analysis of digestion mixtures of eosinophil phospholipase D and synthetic lecithin revealed the liberation of phosphatidic acid alone. Taken together, these data would indicate that the eosinophil contains phospholipase D of restricted physicochemical characteristics.

The eosinophil phospholipase D exhibited an apparent mol wt of 50,000 (Fig. 5) as compared to the cabbage phospholipase D which filtered with an apparent mol wt of 100,000, and phospholipase D from plant sources whose mol wt ranged from 100,000 to 200,000 (18-20). The pH optimum of 4.5-6.0 for the eosinophil phospholipase D is entirely compatible with that observed for plant phospholipase D obtained from peanut and cabbage (18, 19). The pl of partially purified human eosinophil phospholipase D was 5.8-6.2, while that of the whole eosinophil extract on sucrose gradient columns was 4.8-5.0. The latter is comparable with the value of 4.65 observed for the peanut enzyme (19).

A natural substrate of both eosinophil and cabbage phospholipase D would appear to be a mediator of immediate type hypersensitivity reactions, a PAF activity. The PAF activity was produced in the peritoneal cavities of rats prepared with hyperimmune antiserum rich in IgGa and challenged with specific antigen. The activity was ethanol extracted, separated from water soluble mediators on XAD-2, and recovered from silicic acid chromatography in the fraction previously noted to contain SRS-A (14). In contrast to SRS-A (21, 22), the PAF activity was stable to treatment with arylsulfatase B. The capacity of eosinophil phospholipase D, defined by choline liberation from L-α-phosphatidyl choline, to inactivate the PAF activity during sequential purification of the enzyme on DE-52 (Fig. 4), Sephadex G-100 (Fig. 5), and CM-52 is consistent with lecithin and this PAF being substrates of a single protein. This conclusion is supported by the additional finding that both activities focus in a comparable isoelectric region on polyacrylamide gels (Fig. 6). Although only partially purified, phospholipase D extracted from cabbage also exhibited both activities. The enzymatic nature of the interaction between phospholipase D and PAF is indicated by the time-dependent inactivation (Fig. 8) and the finding that higher enzyme to substrate ratios achieved greater inactivation in the same time period (Fig. 7). That a single active site is involved in lecithin cleavage and PAF inactivation of a PAF activity was not established, but is consistent with the finding that the presence of one substrate suppressed the cleavage or inactivation of the other.

Phospholipase D has previously been recognized in mammals only in rat brain (23), and thus its demonstration in human eosinophils represents its initial recognition in primates. Its presence in the eosinophil is particularly noteworthy, since this cell type is directed to the site of immediate type hypersensitivity reactions by specific tetrapeptide chemotactic principles designated eosinophil chemotactic factor of anaphylaxis (12, 24). The eosinophil has been previously recognized to contain arylsulfatase B, which inactivates SRS-A (22), and to share with the neutrophil the capacity to inactivate histamine through its content of histaminase (25). The eosinophil is now appreciated to contain also an enzyme capable of destroying an additional mediator with PAF activity. It should be noted however that the PAF activity derived by an IgGa antibody-mediated reaction in the rat need not be identical with that elaborated by other activating reactions involving different cell sources (4, 5, 8, 9).

**ACKNOWLEDGMENTS**

This work was supported by grants AI-07722 and AI-10356 from the National Institutes of Health.

**REFERENCES**


*Isolation of Human Eosinophil Phospholipase D* 1179


